SAN CARLOS, Calif., June 4, 2014 (GLOBE NEWSWIRE) -- Natus Medical Incorporated (Nasdaq:BABY) today announced the launch of its newest hearing screening product, the Echo-Screen® III hearing screener. Combining new advanced capabilities, with its proven and trusted screening technologies, this next generation Echo-Screen III handheld device comes in any combination of modalities: TEOAE, DPOAE, and ABR.
"I am very pleased to see the impressive results and unique design of this product development effort, building upon our reputation as the global pioneer and worldwide leader in newborn hearing screening," said Jim Hawkins, President and Chief Executive Officer of the Company. "We believe this next generation product will be well received by our International customers as hearing screening adoption continues to grow worldwide."
Natus, the global leader in newborn hearing screening solutions, has manufactured and sold Echo-Screen technology for the past decade under a variety of brand names including Echo-Screen and Accuscreen®. Only Natus manufactured devices incorporate its proprietary technology and algorithms used in tens of millions of newborn hearing screenings worldwide. The new Echo-Screen III is being launched outside the United States with FDA clearance expected later this year.
About Natus Medical Incorporated
Natus is a leading provider of healthcare products used for the screening, detection, treatment, monitoring and tracking of common medical ailments in newborn care, hearing impairment and neurological dysfunction.
Additional information about Natus Medical can be found at www.natus.com.
Accuscreen® is a registered trademark of GN Otometrics.
CONTACT: COMPANY CONTACT: Natus Medical Incorporated Jonathan A. Kennedy Sr. Vice President and Chief Financial Officer (650) 802-0400 InvestorRelations@Natus.comSource:Natus Medical Incorporated